Supaglutide alfa: holding an “ultra-long-acting” trump card, can Yinnuo Pharma play differentiation in the GLP-1 red ocean?

Yinnuo Pharma was founded by Professor Wang Qinghua and is a typical “single core asset” biotech. It raised about RMB 1.558 billion cumulatively in 2020–2024, with a post-money valuation of about RMB 4.65 billion in its latest round (early 2024); in August 2025 it listed in Hong Kong at an offer price of HK$18.68, raising about HK$683 million. Unlike a year earlier when it “had no revenue yet”, in 2025 Yinuoqing achieved revenue of about RMB 131.5 million, and the company formally entered the commercial validation stage — the new starting point for understanding all its subsequent strategic choices.

Yinuoqing itself is the most easily misread. It is not a lipidated synthetic peptide like semaglutide or tirzepatide, but a recombinant fusion protein joining human GLP-1 to a human IgG2 Fc fragment — by molecular lineage, its true “peer” is actually dulaglutide (a GLP-1–IgG4 Fc fusion protein), not semaglutide. This determines that its manufacturing is a fermentation + purification biologics route, and also determines its core selling point: using Fc recycling to stretch the half-life very long. Note that half-life is population-specific — the company commonly used about 204 hours during diabetes development, while its latest annual report says the half-life in overweight/obese populations is about 280 hours; the two should not be mixed, and still less should a single number be taken to make a blanket claim of “longest”.

Put qualifiers on the word “first”: human-sequence GLP-1s are not unprecedented in China — Benemae’s beinaglutide is human-sequence, but it is short-acting (three times daily). So Yinuoqing’s accurate position is: China’s first “ultra-long-acting (weekly formulation, with every-two-weeks explored clinically) human-sequence” GLP-1 fusion protein, and the first of this kind to enter the NRDL. “Longest half-life” is the company’s claim, best treated as a selling point rather than a conclusion.

Market size was never the problem. China has about 140 million adults with diabetes and hundreds of millions with overweight/obesity — the floor of the GLP-1 story. But in the China of 2026, GLP-1 is long since not a blank market — semaglutide, dulaglutide, tirzepatide, mazdutide and ecnoglutide are all on sale. The pure “efficacy gap” is narrowing fast; what really remains unfilled is adherence and affordability.

These are exactly the two points Yinuoqing positions on: first, dosing frequency — if “every two weeks” continues to hold in Phase 3, it will have a convenience selling point peers find hard to replicate (already preliminarily supported by the IIb data, detailed in the next section); second, price — before NRDL entry it was priced at RMB 268.99 for 1 mg and RMB 623.72 for 3 mg, about 64% and 87% of Ozempic’s NRDL price respectively, with affordability rising further after NRDL coverage.

The glucose-lowering evidence itself is solid: two Phase 3 trials, more than 1,100 patients, more than 110 centers, 24 weeks double-blind, with monotherapy at 1 mg lowering HbA1c by 1.73% and at 3 mg by 2.15% (P<0.001 vs placebo); the result of a 1.80% HbA1c reduction at 24 weeks in the 3 mg arm on a metformin background was published in Nature Communications in 2026 as the SUPER 2 study. It should be noted that ranking it directly against the reductions of semaglutide and tirzepatide is not rigorous — baselines, background therapy, doses and statistical methods all differ, so cross-trial comparison can only say it is in the common range for its class; there is currently no head-to-head evidence. It is not a drug that wins by crushing on glucose-lowering magnitude, but by the combination of “good enough + longer-acting + more accessible”.

“Human sequence, low immunogenicity” is the most talked-about and most caution-worthy point in this combination. In theory, the closer to natural human GLP-1, the less likely to induce anti-drug antibodies, and the lower the potential for long-term loss of efficacy and allergy risk; but humanization in itself does not automatically equal lower clinical immunogenicity, and this advantage still lacks direct comparative data against other GLP-1s, requiring post-marketing real-world evidence on antibodies and efficacy maintenance to back it up. Treating it as “a flanking advantage still to be proven” is safer than treating it as an established selling point.

Counting competitors by “the Chinese market” rather than by company nationality, Yinuoqing faces an extremely crowded table where a price war is under way. All imported originators have landed in China and cut prices, and domestic peers have been approved one after another:

*Commercialization of ecnoglutide in mainland China has been taken on by Pfizer China (see Section 6). The scope of approved indications in the “NRDL” column is subject to official notices. Dates in the table are NMPA approval dates.

Read this table and two things are clear at a glance. In the glucose-lowering column, Yinuoqing is not late — it even obtained NRDL status earlier than mazdutide and ecnoglutide, its most tangible current lead. In the weight-loss column, it is the only one still “in Phase 3”: by the time it gets its Phase 3 topline in H2 2026, several peers will already be on sale and the end-market price war will already have started — tirzepatide cut its e-commerce price by about 80%, semaglutide proactively cut its price by about 50%, and semaglutide’s patent is still counting down. It will have to squeeze, with weight-loss data about to be released but already preliminarily shown to be competitive, into a market where prices have already started moving.

This is the biggest change compared with a year ago. Yinuoqing’s weight-loss program no longer has “only a few weeks of early signals” — in 2025 its Phase IIb met its primary endpoint: after 18 weeks of treatment, the 20 mg once-weekly arm lost an average of about 10.6% of body weight and about 8.9 cm of waist circumference, with a trend toward “fat loss while preserving muscle” in body composition, and GI reactions mainly mild. More crucial is the “every two weeks” line — the 20 mg every-two-weeks arm also reached about 9.7% at 18 weeks, not far from once weekly. This amounts to a preliminary clinical answer to its most central differentiation question: the low-frequency dosing enabled by ultra-long action is not just an idea on a slide, but may genuinely hold up in weight loss. Moreover, no clear weight-loss plateau had appeared by the IIb readout, meaning longer treatment still has room to go further.

This shifts the suspense from “does it lose enough weight” to three more precise questions, all riding on the pivotal Phase 3 that has completed enrollment (ENLIGHT, 1,003 patients, 30-week primary endpoint, 48-week secondary endpoint): first, can weight loss at 30 and even 48 weeks keep widening from the IIb base; second, can “every two weeks” maintain efficacy over longer treatment; third, can safety and discontinuation rates support a truly commercializable differentiated label. For reference, among competitors ecnoglutide showed average weight loss of about 15.4% at 48 weeks in Chinese patients (about 15.1% placebo-adjusted), with 92.8% achieving clinically meaningful weight loss — the yardstick Yinuoqing’s Phase 3 will need to engage with.

Market structure is another layer of pressure. GLP-1s in China are sliding from “innovative drug pricing” to “a price war in a quasi-essential category”: on e-commerce, tirzepatide draws traffic with “20% of the price” and “from RMB 480/month”, semaglutide proactively halved its price, and after patent expiry domestic biosimilars (Huadong, Jiuyuan, Livzon, Sino Biopharm, Qilu, etc.) will push glucose-lowering prices lower still. For a drug built on “long-acting + accessible”, the price war is both home ground and a test — home ground because it was already priced affordably and is on the NRDL; a test because, as a fusion protein, its manufacturing complexity and future ability to reduce costs remain to be seen, and it cannot simply be assumed that it can go down indefinitely like a small synthetic peptide.

Yinuoqing is an almost “textbook” China-first route: registration completed on more than a thousand local patients, the Chinese market as the main battlefield, and its own commercial team building channels. This road works in China on three hard supports:

First, the patient base and care pathways are all in China. Glucose-lowering and weight loss need no special companion diagnostics, and GLP-1s are long since written into guidelines (Yinuoqing is already recommended in the National Primary Care Guidelines for Diabetes Prevention and Treatment); the resistance a single product faces is mainly access rather than education, and the NRDL has already opened half of that gate for it.

Second, accessibility is one of the decisive factors in the Chinese market. It should be clarified that NRDL status is not an exclusive advantage over “all” imported drugs — the diabetes indications of semaglutide and tirzepatide are also on the NRDL. Yinuoqing’s real NRDL lead is relative to newly approved domestic peers such as mazdutide and ecnoglutide that are not yet on the NRDL: in the time gap before they get NRDL status, Yinuoqing has a first-mover advantage in primary care and broad-coverage settings.

Third, the local data are self-consistent. Registration rests entirely on the Chinese population, with no reliance on overseas bridging, giving high regulatory certainty.

But an easily formed wrong impression must be corrected: it is not a purely inward-looking company that “only kept a NASH option”. Besides the US FDA clearance for NASH/MASH, it received China MASH clinical approval in March 2025; it is running an obesity/overweight Phase II in Australia that completed enrollment in November 2025, exploring weekly/biweekly/monthly dosing frequencies at once; diabetes BLAs have been filed in Hong Kong and some Southeast Asian and Latin American markets; and in China adolescent obesity and a once-monthly formulation are also advancing. This means its globalization is not a low-investment call option, but a net being spread across multiple points — although registration-grade studies of the core diabetes and weight-loss indications for mainstream US and European markets have not yet started, and the “real value” of going global still depends on these early moves gradually paying off.

First, manufacturing. As a recombinant fusion protein, Yinuoqing takes the biologics route of cell expression + purification rather than the solid-phase route of synthetic peptides. The upside is that the process has been proven with the launch and stability and shelf life meet standards; what needs watching is its manufacturing complexity and ability to reduce costs at scale — fusion proteins and small synthetic peptides have different structures of scale, yield, purification and raw material cost, and which has the better unit cost cannot be generalized. But in a market where even tirzepatide can be discounted to 20%, whoever can bring costs down and ramp capacity faster will matter as much as clinical data. Once weight loss is approved, capacity expansion and cost reduction will immediately become the main battlefield.

Now the partnership template. On February 24, 2026, Sciwind and Pfizer China reached a commercialization collaboration on ecnoglutide: Sciwind can receive up to about US$495 million (upfront + approval + sales milestones), Pfizer obtains exclusive commercialization rights in mainland China for the product, and Sciwind retains marketing authorization holder status and remains responsible for R&D, registration, manufacturing and supply. Note that this is neither a global license selling the molecule nor an acquisition, but a China commercialization division of labor of “I keep manufacturing and the license, you sell it for me”.

For Yinnuo this is both a warning and a reference. The warning: multinational commercial resources in China are scarce, and Sciwind has already signed one. The reference: this structure of “keep the license + outsource commercialization”, for a single-asset company building its own commercial team while also funding a large weight-loss trial, is an option worth seriously evaluating — it can shift channels and part of the cash pressure away in exchange for an upfront and sales milestones. But it should be stressed that this is an “option”, not a “must” — with Yinnuo’s current cash position, it can negotiate at leisure rather than being forced to.

First lay out the 2025 accounts: revenue of about RMB 131.5 million, a full-year loss of about RMB 341.4 million, R&D expenses of about RMB 205.8 million, and selling and distribution expenses of about RMB 176.6 million. At year-end, the company held cash and cash equivalents of about RMB 969 million, plus about RMB 130 million in wealth management products and about RMB 105 million in time deposits over three months, with net current assets of about RMB 974 million. This is a balance sheet of “already spending on commercialization, but with considerable ammunition still on the books”.

So the more accurate judgment is not “cash must hold out until a partnership upfront arrives”, but: the key thing to watch in 2026 is the cash balance between commercial expenses, clinical spending and NRDL-driven uptake. On one side, the large weight-loss trial, commercial team expansion and low-margin distribution under the price war keep consuming money; on the other, uptake after the diabetes indication entered the NRDL and primary-care guidelines is replenishing it. Which force runs faster will determine whether it is relaxed or stretched around the Phase 3 readout — but with nearly RMB 1 billion in liquidity at present, it is not yet “urgent”.

This also amplifies the significance of the Phase 3 readout: it will affect in one go the valuation of any refinancing, the bargaining chips for potential BD, and the pace of resource deployment for weight-loss commercialization. For a single-asset company, pre-setting clear “continue/stop” criteria for this readout is necessary — although for Yinnuo, “stopping” is almost tantamount to “rebuilding the company”, so it is never easy to execute.

A year ago, Yinuoqing still looked like a single-asset bet with “no revenue and uncertain weight loss”; today its portrait is much clearer: the diabetes indication is launched, on the NRDL and in primary-care guidelines, the weight-loss IIb has read out in double digits with every-two-weeks dosing validated, and the company still has nearly RMB 1 billion in liquidity. It is not a laggard left behind by the red ocean, but a challenger holding real long-acting differentiation, already earning money, and waiting for the pivotal Phase 3 to cash that differentiation in as value.

The Phase 3 readout in H2 2026 will answer three questions in one go: what the long-acting Q2W differentiation is worth, whether the magnitude of weight loss can stand up in the red ocean, and whether Yinnuo needs a partner — and with what posture. Until then, turning the long-acting selling point into registration evidence, using the NRDL to capture diabetes cash flow, and holding the line on compliance and cash balance — these three things will determine how far it can play this good hand.